Skip to main content
Top
Published in: Virology Journal 1/2019

Open Access 01-12-2019 | Human Immunodeficiency Virus | Research

Human immunodeficiency virus type 1 ((HIV-1) subtypes in the northwest region, Cameroon

Authors: Lem Edith Abongwa, Anthony Kebira Nyamache, Judith Ndongo Torimiro, Paul Okemo, Fokunang Charles

Published in: Virology Journal | Issue 1/2019

Login to get access

Abstract

Background

The high genetic diversity of HIV-1 has been shown to influence the global distribution, disease progression, treatment success, and the development of an effective vaccine. Despite the low HIV prevalence in Cameroon, all the major HIV subtypes alongside several circulating recombinant forms (CRFs) and unique recombinant forms (URFs) have been reported in Cameroon. To date, HIV-1 diversity in some parts of Cameroon has been largely studied however, information on circulating HIV-1 subtypes in the Northwest region (NWR) of Cameroon is dearth. Therefore the aim of this study was to determine the current circulating HIV-1 subtypes among adults in the NWR of Cameroon.

Methods

The genetic analysis of the reverse transcriptase region of the pol gene was performed on 81 samples. The samples were collected from drug naïve patients aged between 18 and 61 years residing within the rural and urban towns in the NWR during the period between February and April 2016. Viral RNA was extracted from plasma, reverse-transcribed, further amplified by nested-PCR before sequencing using an in-house protocol. Generated sequences were then phylogenetically analyzed together with references using MEGA 7.

Results

Phylogenetic analysis revealed a broad viral diversity including CRF02 _AG (74.1%), F2 (7.4%), D (7.4%), G (3.7%), A1 (1.2%), CRF22_01A1 (2.5%), CRF06_cpx (1.2%), CRF09_cpx (1.2%), CRF11_cpx (1.2%). Three close epidemic clusters were found among F2 (1) and CRF02_AG (2) variants. For the first time we are reporting the CRF22_01A1 subtype in this region.

Conclusion

Our findings update HIV-1 subtypes information in Cameroon and uphold previous studies that CRF02_AG is the most prevalent subtype. This CRF02_AG subtype may have important public health, research, and clinical consequences.
Literature
1.
go back to reference http://www .hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html, Accessed 09 April 2019. http://www .hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html, Accessed 09 April 2019.
2.
go back to reference Véras NM, Santoro MM, Gray RR, Tatem AJ, Presti AL, Olearo F, et al. Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy. AIDS Res Hum Retrovir. 2011;27(11):1173–82.CrossRef Véras NM, Santoro MM, Gray RR, Tatem AJ, Presti AL, Olearo F, et al. Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy. AIDS Res Hum Retrovir. 2011;27(11):1173–82.CrossRef
3.
go back to reference Patiño-Galindo JÁ, Torres-Puente M, Bracho MA, Alastrué I, Juan A, Navarro D, et al. The molecular epidemiology of HIV-1 in the Comunidad Valenciana (Spain): analysis of transmission clusters. Sci Rep. 2017;7(1):11584.CrossRef Patiño-Galindo JÁ, Torres-Puente M, Bracho MA, Alastrué I, Juan A, Navarro D, et al. The molecular epidemiology of HIV-1 in the Comunidad Valenciana (Spain): analysis of transmission clusters. Sci Rep. 2017;7(1):11584.CrossRef
4.
go back to reference De Oliveira F, Mourez T, Vessiere A, Ngoupo PA, Alessandri-Gradt E, Simon F, et al. Multiple HIV-1/M+ HIV-1/O dual infections and new HIV-1/MO inter-group recombinant forms detected in Cameroon. Retrovirology. 2017;14(1):1.CrossRef De Oliveira F, Mourez T, Vessiere A, Ngoupo PA, Alessandri-Gradt E, Simon F, et al. Multiple HIV-1/M+ HIV-1/O dual infections and new HIV-1/MO inter-group recombinant forms detected in Cameroon. Retrovirology. 2017;14(1):1.CrossRef
5.
go back to reference Tebit DM, Zekeng L, Kaptué L, Salminen M, Kräusslich HG, Herchenröder O. Genotypic and phenotypic analysis of HIV type 1 primary isolates from western Cameroon. AIDS Res Hum Retrovir. 2002;18(1):39–48.CrossRef Tebit DM, Zekeng L, Kaptué L, Salminen M, Kräusslich HG, Herchenröder O. Genotypic and phenotypic analysis of HIV type 1 primary isolates from western Cameroon. AIDS Res Hum Retrovir. 2002;18(1):39–48.CrossRef
6.
go back to reference Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2(4):e112.CrossRef Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2(4):e112.CrossRef
7.
go back to reference Santoro MM, Perno CF. HIV-1 genetic variability and clinical implications. ISRN microbiology. 2013;2013. Santoro MM, Perno CF. HIV-1 genetic variability and clinical implications. ISRN microbiology. 2013;2013.
8.
go back to reference Mbanya D, Sama M, Tchounwou P. Current status of HIV/AIDS in Cameroon: how effective are control strategies? Int J Environ Res Public Health. 2008;5(5):378–83.CrossRef Mbanya D, Sama M, Tchounwou P. Current status of HIV/AIDS in Cameroon: how effective are control strategies? Int J Environ Res Public Health. 2008;5(5):378–83.CrossRef
10.
go back to reference Agyingi L, Mayr LM, Kinge T, Orock GE, Ngai J, Asaah B, et al. The evolution of HIV-1 group M genetic variability in southern Cameroon is characterized by several emerging recombinant forms of CRF02_AG and viruses with drug resistance mutations. J Med Virol. 2014;86(3):385–93.CrossRef Agyingi L, Mayr LM, Kinge T, Orock GE, Ngai J, Asaah B, et al. The evolution of HIV-1 group M genetic variability in southern Cameroon is characterized by several emerging recombinant forms of CRF02_AG and viruses with drug resistance mutations. J Med Virol. 2014;86(3):385–93.CrossRef
11.
go back to reference Teto G, Tagny CT, Mbanya D, Fonsah JY, Fokam J, Nchindap E, et al. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG-and non-CRF02_AG-infected patients in Yaoundé. Cameroon Scientific reports. 2017;7(1):14136.CrossRef Teto G, Tagny CT, Mbanya D, Fonsah JY, Fokam J, Nchindap E, et al. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG-and non-CRF02_AG-infected patients in Yaoundé. Cameroon Scientific reports. 2017;7(1):14136.CrossRef
12.
go back to reference Burda ST, Konings FA, Williams CA, Anyangwe C, Nyambi PN. HIV-1 CRF09_cpx circulates in the north West Province of Cameroon where CRF02_AG infections predominate and recombinant strains are common. AIDS Research & Human Retroviruses. 2004;20(12):1358–63.CrossRef Burda ST, Konings FA, Williams CA, Anyangwe C, Nyambi PN. HIV-1 CRF09_cpx circulates in the north West Province of Cameroon where CRF02_AG infections predominate and recombinant strains are common. AIDS Research & Human Retroviruses. 2004;20(12):1358–63.CrossRef
13.
go back to reference Bosire EM, Nyamache AK, Gicheru MM, Khamadi SA, Lihana RW, Okoth V. Population specific reference ranges of CD3, CD4 and CD8 lymphocyte subsets among healthy Kenyans. AIDS Res Ther. 2013;10(1):24.CrossRef Bosire EM, Nyamache AK, Gicheru MM, Khamadi SA, Lihana RW, Okoth V. Population specific reference ranges of CD3, CD4 and CD8 lymphocyte subsets among healthy Kenyans. AIDS Res Ther. 2013;10(1):24.CrossRef
14.
go back to reference Fokam J, Salpini R, Santoro MM, Cento V, D’Arrigo R, Gori C, et al. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virol. 2011;156(7):1235–43.CrossRef Fokam J, Salpini R, Santoro MM, Cento V, D’Arrigo R, Gori C, et al. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virol. 2011;156(7):1235–43.CrossRef
15.
go back to reference Nyamache AK, Muigai AW, Nganga Z, Khamadi SA. HIV type 1 genetic diversity and naturally occurring polymorphisms in HIV type 1 Kenyan isolates: implications for integrase inhibitors. AIDS Res Hum Retrovir. 2012 1;28(8):933–6.CrossRef Nyamache AK, Muigai AW, Nganga Z, Khamadi SA. HIV type 1 genetic diversity and naturally occurring polymorphisms in HIV type 1 Kenyan isolates: implications for integrase inhibitors. AIDS Res Hum Retrovir. 2012 1;28(8):933–6.CrossRef
16.
go back to reference Ceccarelli L, Salpini R, Moudourou S, Cento V, Santoro MM, Fokam J, et al. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. J Med Virol. 2012;84(5):721–7.CrossRef Ceccarelli L, Salpini R, Moudourou S, Cento V, Santoro MM, Fokam J, et al. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. J Med Virol. 2012;84(5):721–7.CrossRef
17.
go back to reference Courtney CR, Agyingi L, Fokou A, Christie S, Asaah B, Meli J, et al. Monitoring HIV-1 group M subtypes in Yaounde, Cameroon reveals broad genetic diversity and a novel CRF02_AG/F2 infection. AIDS Res Hum Retrovir. 2016;32(4):381–5.CrossRef Courtney CR, Agyingi L, Fokou A, Christie S, Asaah B, Meli J, et al. Monitoring HIV-1 group M subtypes in Yaounde, Cameroon reveals broad genetic diversity and a novel CRF02_AG/F2 infection. AIDS Res Hum Retrovir. 2016;32(4):381–5.CrossRef
18.
go back to reference Ndembi N, Abraha A, Pilch H, Ichimura H, Mbanya D, Kaptue L, et al. Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol. 2008;46(1):177–84.CrossRef Ndembi N, Abraha A, Pilch H, Ichimura H, Mbanya D, Kaptue L, et al. Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol. 2008;46(1):177–84.CrossRef
19.
go back to reference Negedu-Momoh OR, Olonitola OS, Odama LE, Inabo HI, Mbah HA, Kasembeli AN, et al. Antiretroviral-drug resistant mutations and genetic diversity in HIV-1 infected individuals in Nigeria. World Journal of AIDS. 2014;4(02):187.CrossRef Negedu-Momoh OR, Olonitola OS, Odama LE, Inabo HI, Mbah HA, Kasembeli AN, et al. Antiretroviral-drug resistant mutations and genetic diversity in HIV-1 infected individuals in Nigeria. World Journal of AIDS. 2014;4(02):187.CrossRef
20.
go back to reference Carr JK, Wolfe ND, Torimiro JN, Tamoufe U, Mpoudi-Ngole E, Eyzaguirre L, Birx DL, McCutchan FE, Burke DS. HIV-1 recombinants with multiple parental strains in low-prevalence, remote regions of Cameroon: evolutionary relics? Retrovirology. 2010;7(1):39.CrossRef Carr JK, Wolfe ND, Torimiro JN, Tamoufe U, Mpoudi-Ngole E, Eyzaguirre L, Birx DL, McCutchan FE, Burke DS. HIV-1 recombinants with multiple parental strains in low-prevalence, remote regions of Cameroon: evolutionary relics? Retrovirology. 2010;7(1):39.CrossRef
21.
go back to reference Powell R, Barengolts D, Mayr L, Nyambi P. The evolution of HIV-1 diversity in rural Cameroon and its implications in vaccine design and trials. Viruses. 2010;2(2):639–54.CrossRef Powell R, Barengolts D, Mayr L, Nyambi P. The evolution of HIV-1 diversity in rural Cameroon and its implications in vaccine design and trials. Viruses. 2010;2(2):639–54.CrossRef
23.
go back to reference Billong SC, Fokam J, Aghokeng AF, Milenge P, Kembou E, Abessouguie I, et al. Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance. PLoS One. 2013;8(8):e72680.CrossRef Billong SC, Fokam J, Aghokeng AF, Milenge P, Kembou E, Abessouguie I, et al. Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance. PLoS One. 2013;8(8):e72680.CrossRef
24.
go back to reference Fokam J, Elat JB, Billong SC, Kembou E, Nkwescheu AS, Obam NM, et al. Monitoring HIV drug resistance early warning indicators in Cameroon: a study following the revised World Health Organization recommendations. PLoS One. 2015;10(6):e0129210.CrossRef Fokam J, Elat JB, Billong SC, Kembou E, Nkwescheu AS, Obam NM, et al. Monitoring HIV drug resistance early warning indicators in Cameroon: a study following the revised World Health Organization recommendations. PLoS One. 2015;10(6):e0129210.CrossRef
25.
go back to reference Fokam J, Bellocchi MC, Armenia D, Nanfack AJ, Carioti L, Continenza F, et al. Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. Medicine. 2018;97(13):e0176.CrossRef Fokam J, Bellocchi MC, Armenia D, Nanfack AJ, Carioti L, Continenza F, et al. Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. Medicine. 2018;97(13):e0176.CrossRef
26.
go back to reference Tchouwa GF, Eymard-Duvernay S, Cournil A, Lamare N, Serrano L, Butel C, et al. Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey. J Antimicrob Chemother. 2018. Tchouwa GF, Eymard-Duvernay S, Cournil A, Lamare N, Serrano L, Butel C, et al. Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey. J Antimicrob Chemother. 2018.
27.
go back to reference Vergne L, Diagbouga S, Kouanfack C, Aghokeng A, Butel C, Laurent C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther. 2006;11(5):575–9.PubMed Vergne L, Diagbouga S, Kouanfack C, Aghokeng A, Butel C, Laurent C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther. 2006;11(5):575–9.PubMed
28.
go back to reference Mbunkah HA, Marzel A, Schmutz S, Kok YL, Zagordi O, Shilaih M, et al. Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-16. J Antimicrob Chemother. 2018. Mbunkah HA, Marzel A, Schmutz S, Kok YL, Zagordi O, Shilaih M, et al. Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-16. J Antimicrob Chemother. 2018.
30.
go back to reference Machnowska P, Hauser A, Meixenberger K, Altmann B, Bannert N, Rempis E, et al. Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT. PLoS One. 2017;12(5):e0178297.CrossRef Machnowska P, Hauser A, Meixenberger K, Altmann B, Bannert N, Rempis E, et al. Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT. PLoS One. 2017;12(5):e0178297.CrossRef
31.
go back to reference Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, et al. 2017 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine. 2017;24(4):132.PubMed Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, et al. 2017 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine. 2017;24(4):132.PubMed
32.
go back to reference Teto G, Tagny CT, Mbanya D, Fonsah JY, Fokam J, Nchindap E, et al. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon. Sci Rep. 2017;7(1):14136.CrossRef Teto G, Tagny CT, Mbanya D, Fonsah JY, Fokam J, Nchindap E, et al. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon. Sci Rep. 2017;7(1):14136.CrossRef
33.
go back to reference De Luca A, Sidumo ZJ, Zanelli G, Magid NA, Luhanga R, Brambilla D, et al. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique. BMC Infect Dis. 2017;17(1):605.CrossRef De Luca A, Sidumo ZJ, Zanelli G, Magid NA, Luhanga R, Brambilla D, et al. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique. BMC Infect Dis. 2017;17(1):605.CrossRef
Metadata
Title
Human immunodeficiency virus type 1 ((HIV-1) subtypes in the northwest region, Cameroon
Authors
Lem Edith Abongwa
Anthony Kebira Nyamache
Judith Ndongo Torimiro
Paul Okemo
Fokunang Charles
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2019
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-019-1209-6

Other articles of this Issue 1/2019

Virology Journal 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.